Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderately to Severely Active Crohn's Disease.
Allez M, Sands BE, Feagan BG, D'Haens G, De Hertogh G, Randall CW, Zou B, Johanns J, O'Brien C, Curran M, Rebuck R, Wang ML, Sabins N, Baker T, Kobayashi T. Allez M, et al. Among authors: randall cw. J Crohns Colitis. 2023 Aug 21;17(8):1235-1251. doi: 10.1093/ecco-jcc/jjad047. J Crohns Colitis. 2023. PMID: 36939629 Clinical Trial.
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV Jr, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ; SEAVUE Study Group. Sands BE, et al. Lancet. 2022 Jun 11;399(10342):2200-2211. doi: 10.1016/S0140-6736(22)00688-2. Lancet. 2022. PMID: 35691323 Clinical Trial.
Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease.
Sandborn WJ, Bhandari BR, Randall C, Younes ZH, Romanczyk T, Xin Y, Wendt E, Chai H, McKevitt M, Zhao S, Sundy JS, Keshav S, Danese S. Sandborn WJ, et al. J Crohns Colitis. 2018 Aug 29;12(9):1021-1029. doi: 10.1093/ecco-jcc/jjy049. J Crohns Colitis. 2018. PMID: 29767728 Free PMC article. Clinical Trial.
Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials.
Loftus EV Jr, Colombel JF, Schreiber S, Randall CW, Regueiro M, Ali T, Arendt C, Coarse J, Spearman M, Kosutic G. Loftus EV Jr, et al. Among authors: randall cw. Clin Gastroenterol Hepatol. 2016 Dec;14(12):1753-1762. doi: 10.1016/j.cgh.2016.07.019. Epub 2016 Jul 25. Clin Gastroenterol Hepatol. 2016. PMID: 27464588 Free article. Clinical Trial.
Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study.
Sandborn WJ, Melmed GY, McGovern DP, Loftus EV Jr, Choi JM, Cho JH, Abraham B, Gutierrez A, Lichtenstein G, Lee SD, Randall CW, Schwartz DA, Regueiro M, Siegel CA, Spearman M, Kosutic G, Pierre-Louis B, Coarse J, Schreiber S. Sandborn WJ, et al. Among authors: randall cw. Aliment Pharmacol Ther. 2015 Aug;42(3):330-42. doi: 10.1111/apt.13251. Epub 2015 Jun 1. Aliment Pharmacol Ther. 2015. PMID: 26031921 Free article. Clinical Trial.
Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study.
Lee SD, Rubin DT, Sandborn WJ, Randall C, Younes Z, Schreiber S, Schwartz DA, Burakoff R, Binion D, Dassopoulos T, Arsenescu R, Gutierrez A, Scherl E, Kayhan C, Hasan I, Kosutic G, Spearman M, Sen D, Coarse J, Hanauer S. Lee SD, et al. Inflamm Bowel Dis. 2016 Aug;22(8):1870-80. doi: 10.1097/MIB.0000000000000805. Inflamm Bowel Dis. 2016. PMID: 27400222 Free PMC article. Clinical Trial.
44 results